PMID: 3756357Oct 1, 1986Paper

Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia

Blut
E R GrümayerH Gadner

Abstract

Seventeen children and two adolescents, aged 6 months to 20 9/12 years, with poor risk leukemia were treated with a total of 38 sequential high-dose ARA-C-Asparaginase courses (HIDAC-ASNase). Each course was followed by profound myelosuppression. Fever occurred in 13.2% and infectious complications in 7.9% of courses. Other side effects were vomiting (81.6%), drug fever (55.3%), mucositis and diarrhoea (28.9%), mild hepatotoxicity (26.3%), exanthemas (18.4%), conjunctivitis (15.8%), local ASNase hypersensitivity (7.9%), athropathy (5.3%). One patient developed generalized seizures followed by coma and death. The possible association between ARA-C, the CNS symptoms and death could neither be demonstrated nor excluded. Except for the possible ARA-C related CNS toxicity, toxic effects were reversible. We consider this treatment a tolerable chemotherapeutic contribution in childhood.

References

Feb 1, 1983·Cancer·M C SalinskyH S Schutta
Jan 1, 1984·Cancer Chemotherapy and Pharmacology·A RohatinerT A Lister
Jul 1, 1982·British Journal of Haematology·R WillemzeG Colpin
Jan 1, 1982·Medical and Pediatric Oncology·R L Capizzi, Y C Cheng
Mar 1, 1965·Biochemical Pharmacology·M Y CHU, G A FISCHER

❮ Previous
Next ❯

Citations

Mar 16, 2006·Blood·UNKNOWN Children's Oncology GroupStella M Davies
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yves PerelUNKNOWN Group LAME of the French Society of Pediatric Hematology and Immunology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.